Lion Biotechnologies is focused on the development and commercialization of novel cancer immunotherapies based on tumor infiltrating lymphocytes (TILs).  This approach, also known as adoptive T-cell therapy, was developed by Dr. Steven A. Rosenberg at the National Cancer Institute and is currently in use at leading cancer centers in the US.

Our lead product candidate is an autologous, ready-to-infuse cell therapy that has demonstrated distinctive efficacy in the treatment of Stage 4 metastatic melanoma. In Phase 2 clinical trials, patients treated with this product demonstrated objective response rates of 49%, significantly exceeding those associated with existing melanoma treatments.

In addition to metastatic melanoma, our TIL technology is potentially applicable to all solid tumors, including ovarian, colorectal, head and neck, and other cancers.  As we continue advancing our current clinical programs, we are also developing next-generation TILs and an optimized manufacturing process that will enable the production of highly potent, engineered cells at a significantly reduced cost.